Article · UK Corporate Tax & R&D

UK ERIS 30% R&D Intensity Test and 14.5% Payable Credit: Complete Guide

CTA 2009 Chapter 2 worked example comparing 26.97% ERIS cash against 16.20% loss-making Merged RDEC, connected-company rules, and the 1-year grace period

For loss-making R&D-intensive SMEs (loss-making before the 86% additional deduction under CTA 2009 s. 1044(2A)), Enhanced R&D Intensive Support (ERIS) under CTA 2009 Part 13, Chapter 2 delivers up to 26.97% in immediate cash (86% additional deduction + 14.5% payable credit) for accounting periods beginning on or after 1 April 2024. That beats loss-making Merged RDEC (16.20%) by 10.77 percentage points in Year 1 cash, provided the company clears the 30% R&D intensity threshold.

The CTA 2009 s. 1045ZA Intensity Formula & Connected-Company Trap

Reduced from 40% (FY2023) to 30% for accounting periods beginning on or after 1 April 2024, the intensity ratio equals:

R&D Intensity = Qualifying R&D Expenditure (Company + Connected Companies) / Total Relevant Expenditure (Company + Connected Companies)

Total relevant expenditure includes all P&L expenses (including depreciation, share-based payments, and interest) plus capitalized qualifying R&D (s. 1308), aggregated across all connected companies under CTA 2010 s. 1122 (eliminating intercompany double-counting). Importantly, Finance Act 2024 abolished the legacy subsidised expenditure exclusion for both Merged RDEC and ERIS (subject only to the Northern Ireland Windsor Framework de minimis cap in s. 1112J).

Worked Comparison: Fenland BioCompute Ltd (ERIS vs. Merged RDEC)

Fenland BioCompute Ltd (autonomous SME, £1,450,000 revenue, £2,500,000 total relevant expenditure, -£1,050,000 pre-R&D loss) incurs £850,000 of qualifying R&D, achieving an intensity of 34.00% (>= 30.00%):

Metric (Fenland BioCompute Ltd)ERIS (Ch. 2)Merged RDEC (Ch. 1A)Variance
Additional Deduction (86%) / Gross RDEC (20%)£731,000£170,000-
Surrenderable Loss / Step 2 Notional Tax (19%)£1,581,000£32,300-
Immediate Cash Payable by HMRC£229,245 (26.97%)£137,700 (16.20%)+£91,545
Trading Loss Carried Forward£200,000£880,000-£680,000
Step 2 CT Carry-Forward Pool (s. 1042L)£0£32,300-£32,300
Undiscounted Total Value at 25% Future CT£279,245£390,000-£110,755

The One-Year Grace Period & NPV Trade-Off

If Fenland's intensity dips to 27.50% in Year 2 (£770,000 / £2,800,000), the CTA 2009 s. 1045ZA(6) one-year grace period preserves ERIS eligibility for Year 2, delivering £207,669 instead of £124,740 under Merged RDEC (an extra £82,929 in non-dilutive cash). Strategically, ERIS 100% cash surrender wins decisively on NPV for venture-backed biotechs facing 4+ years to profitability, whereas a temporary loss-maker returning to 25% CT within 1-2 years should carry forward losses or use partial surrender.

Free Excel Calculator & Complete Handbook

Run your own UK R&D figures through the live 7-step Merged RDEC, ERIS 30% intensity, and PAYE/NIC cap model in UK_RD_Merged_RDEC_ERIS_Calculator.xlsx, or read the complete 15-chapter practitioner reference in The UK R&D Tax Relief Handbook.

Get the free Excel calculator → View the handbook →

Further reading

Previous: UK Merged RDEC 20% Seven-Step Calculation

Next: UK R&D Contracted-Out Rules, Overseas Restrictions, and PAYE/NIC Cap

Related UK corporate tax handbooks: UK Corporate Interest Restriction · UK VAT Partial Exemption · OECD Pillar Two